Abstract
The four-plate test (FPT) is an animal model of anxiety based on spontaneous response. Animals are exposed to a novel environment. The exploration of this novel surrounding is suppressed by the delivery of mild electric foot shock contingent to quadrant crossing. Animal can only escape from this aversive situation by remaining motionless (passive avoidance). This model of conditioned fear presents several advantages. It is a simple and quick procedure and there is no need for prior training of animals. In this test, benzodiazepines (BZDs) induce a strong antipunishment effect, which has been proposed to be a reflection of their anxiolytic activity. The FPT also allows the detection of anxiolytic effects of other non-BZD anxiolytic compounds such as selective serotonin (5-HT) reuptake inhibitors (SSRI) or mixed serotonin and noradrenaline (NA) reuptake inhibitors (SNRI).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Boissier JR, Simon P, Aron C (1968) A new method for rapid screening of minor tranquillizers in mice. Eur J Pharmacol 4:145–151
Liao JF, Hung WY, Chen CF (2003) Anxiolytic-like effects of baicalein and baicalin in the vogel conflict test in mice. Eur J Pharmacol 464:141–146
Umezu T (1999) Effects of psychoactive drugs in the vogel test in mice. Jpn J Pharmacol 80:111–118
Bourin M, Hascoët M, Mansouri B, Colombel MC, Bradwejn J (1992) Comparison of behavioral effects after single and repeated administrations of four benzodiazepines in three mice behavioral models. J Psychiatry Neurosci 17:72–77
Hascoët M and Bourin M (1997) Anticonflict effect of alpidem as compared with the benzodiazepine alprazolam in Rats. Pharmacol Biochem Behav 2:317–324
Jones GH, Schneider C, Schneider HH, Seidler J, Cole BJ and Stephens DN (1994) Comparison of several benzodiazepine receptor ligands in two models of anxiolytic activity in the mouse: an analysis based on fractional receptor occupancies. Psychopharmacol (Ber) 114:191–199
Sills GJ (2006) The mechanisms of action of gabapentine and pregabalin. Curr Opin Pharmacol. 6:108–113
Taylor CP, Gee NS, Su TZ, Kocsis JD, Welty DF, Brown JP, Dooley DJ, Boden P, Singh L (1998) A summary of mechanistic hypotheses of gabapentine pharmacology. Epilepsy Res 29:233–249
Götz E, Feuerstein TJ, Lais A, Meyer DK (1993) Effects of gabapentine on release of gamma-aminobutyric acid from slices of rat neostriatum. Arzneimittelforschung 43:636–638
Roberto M, Gilpin NW, O’Dell LE, Cruz MT, Morse AC, Siggins GR, Koob GF (2008) Cellular and behavioral interactions of gabapentine with alcohol dependence. J Neurosci 28:5762–5771
Partyka A, Kłodzińska A, Szewczyk B, Wierońska JM, Chojnacka-Wójcik E, Librowski T, Filipek B, Nowak G, Pilc A (2007) Effects of GABAB receptor ligands in rodent tests of anxiety-like behavior. Pharmacol Rep 59:757–762
Feighner JP (1999) Overview of antidepressants currently used to treat anxiety disorders. J Clin Psychiatry 60:18–22
Gorman JM, Kent JM (1999) SSRIs and SNRIs: broad spectrum of efficacy beyond major depression. J Clin Psychiatry 60:33–38
Zohar J, Westenberg HG (20004) Anxiety disorders: a review of tricyclic antidepressants and selective serotonin reuptake inhibitors. Acta Psychiatr Scand Suppl 03:39–49
Rocca P, Fonzo V, Scotta M, Zanalda E, Ravizza L (1997) Paroxetine efficacy in the treatment of generalised anxiety disorder. Acta Psychiatr Scand 95: 444–450
File SE (1985). Animal models for predicting clinical efficacy of anxiolytic drugs: social behaviour. Neuropsychobiology 13:55–62
Linnoila M, Eckhardt M, Durcan M, Lister R, Martin P (1987) Interactions of serotonin with ethanol: clinical and animal studies. Psychopharmacology Bull 23:452–457
Chopin P, Briley M (1987) Animal models of anxiety: the effects of compounds that modify 5-HT neurotransmission. TIPS 8:383–389
Bourin M, Redrobe JP, Hascoet M, Colombel MC, Baker GB (1996) A schematic representation of the psychopharmacological profile of antidepressants. Prog Neuro-Psychopharmacol Biol Psychiat 20:1389–1402
Handley SL, McBlane JW (1992) Opposite effects of fluoxetine in two animal models of anxiety. Br J Pharmacol 107:446P (suppl)
Hascoët M, Bourin M, Colombel MC, Fiocco AJ, Baker GB (2000) Anxiolytic-like effects of antidepressants after acute administration in a four-plate test in mice. Pharmacol Biochem Behav 65:339–344
Hyttel J (1996) Pharmacological characterisation of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol 9:19–26
Redrobe JP, Bourin M, Colombel MC, Baker GB(1998) Dose-dependent noradrenergic and serotonergic properties of venlafaxine in animal models indicative of antidepressant activity. Psychopharmacology 138:1–8
Griebel G (1996) Variability in the effect of 5-HT related compounds in experimental models of anxiety : evidence for multiple mechanism of 5-HT in anxiety or never-ending story?. Polish J Pharmacol 48: 129–136
Eison MS (1989) The new generation of serotonergic anxiolytics: possible clinical roles. Psychopathology 22:13–20
Ables AZ, Baughman OL 3rd (2003) Antidepressants: update on new agents and indications. Am Fam Physician 67:547–554
Bourin M, Lambert O (2002) Pharmacotherapy of anxious disorders. Hum Psychopharmacol 17:383–400
Nemeroff CB (2003) Anxiolytics: past, present, and future agents. J Clin Psychiatry 64:3–6
Vaswani M, Linda FK, Ramesh S (2003) Role of selective serotonin reuptake inhibitors in sychiatric disorders: a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry 27:85–102
Lucki I (1996) Serotonin receptor specificity in anxiety disorders. J Clin Psychiatry 7:5–10
Passchier J, van Waarde A (2001) Visualisation of serotonin-1A (5-HT1A) receptors in the central nervous system. Eur J Nucl Med 28:113–129
Bell C, Abrams J, Nutt D (2001) Tryptophan depletion and its implications for psychiatry. Br J Psychiatry 178:399–405
Murphy DL, Wichems C, Li Q, Heils A (1999) Molecular manipulations as tools for enhancing our understanding of 5-HT neurotransmission. Trends Pharmacol Sci 20:246–252
Zhuang X, Gross C, Santarelli L, Compan V, Trillat AC, Hen R (1999) Altered emotional states in knockout mice lacking 5-HT1A or 5-HT1B receptors. Neuropsychopharmacology 21:52 S-60 S
Griebel G (1995) 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: more than 30 years of research. Pharmacol Ther 65:319–395
Millan MJ (2003) The neurobiology and control of anxious states. Prog Neurobiol 70:83–244.
Hascoët M, Bourin M, Couetoux du Tertre A (1997) Influence of prior experience on mice behavior using the four-plate test. Pharmacol Biochem Behav 58:1131–1138
Hascoët M, Bourin M, Nic Dhonnchadha BA (2000) The influence of buspirone, and its metabolite 1-PP, on the activity of paroxetine in the mouse light/dark paradigm and four plates test. Pharmacol Biochem Behav 67:45–53
Charney DS, Woods SW, Goodman WK, Heninger GR (1987) Serotonin function in anxiety. II. Effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects. Psychopharmacology (Berl) 92:14–24
Hensman R, Guimarães FS, Wang M, Deakin JF (1991) Effects of ritanserin on aversive classical conditioning in humans. Psychopharmacology (Berl) 104:220–224
Griebel G, Perrault G, Sanger DJ (1997) A comparative study of the effects of selective and non-selective 5-HT2 receptor subtype antagonists in rat and mouse models of anxiety. Neuropharmacology 36:793–802
Nic Dhonnchadha BA, Bourin M, Hascoët M (2003) Anxiolytic-like effects of 5-HT2 ligands on three mouse models of anxiety. Behav Brain Res 140:203–214
Nic Dhonnchadha BA, Hascoët M, Jolliet P, Bourin M (2003) Evidence for a 5-HT2A receptor mode of action in the anxiolytic-like properties of DOI in mice. Behav Brain Res 147:175–184
Borsini F, Brambilla A, Cesana R, Donetti A (1993) The effect of DAU 6215, a novel 5HT-3 antagonist, in animal models of anxiety. Pharmacol Res 27:151–164
Dooley DJ, Klamt I (1993) Differential profile of the CCKB receptor antagonist CI-988 and diazepam in the four-plate test. Psychopharmacology (Berl) 112:452–454
Kłodzińska A, Tatarczyńska E, Stachowicz K, Chojnacka-Wójcik E (2004) The anxiolytic-like activity of AIDA (1-aminoindan-1,5-dicarboxylic acid), an mGLu 1 receptor antagonist. J Physiol Pharmacol 55:113–126
Kłodzińska A, Chojnacka-Wójcik E, Pałucha A, Brański P, Popik P, Pilc A (1999) Potential anti-anxiety, anti-addictive effects of LY 354740, a selective group II glutamate metabotropic receptors agonist in animal models. Neuropharmacology 38:1831–1839
Rajarao SJ, Platt B, Sukoff SJ, Lin Q, Bender CN, Nieuwenhuijsen BW, Ring RH, Schechter LE, Rosenzweig-Lipson S, Beyer CE (2007) Anxiolytic-like activity of the non-selective galanin receptor agonist, galnon. Neuropeptides 41:307–320
Klodzinska A, Tatarczyńska E, Chojnacka-Wójcik E, Nowak G, Cosford ND, Pilc A (2004) Anxiolytic-like effects of MTEP, a potent and selective mGlu5 receptor agonist does not involve GABA(A) signaling. Neuropharmacology 47:342–350
Tatarczyńska E, Klodzińska A, Chojnacka-Wójcik E, Palucha A, Gasparini F, Kuhn R, Pilc A (2001) Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. Br J Pharmacol 132:1423–1430
Stachowicz K, Brañski P, Kłak K, van der Putten H, Cryan JF, Flor PJ, Andrzej P (2008) Selective activation of metabotropic G-protein-coupled glutamate 7 receptor elicits anxiolytic-like effects in mice by modulating GABAergic neurotransmission. Behav Pharmacol 19:597–603
Sanger DJ, Joly D (1991) The effects of NMDA antagonists on punished exploration in mice. Behav Pharmacol 2:57–63
Griebel G, Simiand J, Steinberg R, Jung M, Gully D, Roger P, Geslin M, Scatton B, Maffrand JP, Soubrié P (2002) 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1 S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1, 3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor(1) receptor antagonist. II. Characterization in rodent models of stress-related disorders. J Pharmacol Exp Ther 301:333–345
Leonard SK, Dwyer JM, Sukoff Rizzo SJ, Platt B, Logue SF, Neal SJ, Malberg JE, Beyer CE, Schechter LE, Rosenzweig-Lipson S, Ring RH (2008) Pharmacology of neuropeptide S in mice: therapeutic relevance to anxiety disorders. Psychopharmacology (Berl) 197: 601–611
Serradeil-Le Gal C, Wagnon J 3 rd, Tonnerre B, Roux R, Garcia G, Griebel G, Aulombard A (2005) An overview of SSR149415, a selective nonpeptide vasopressin V(1b) receptor antagonist for the treatment of stress-related disorders. CNS Drug Rev 11:53–68
Przegaliński E, Tatarczyńska E, Chojnacka-Wójcik E (1998) Anxiolytic- and antidepressant-like effects of an antagonist at glycineB receptors. Pol J Pharmacol 50:349–354
Ring RH, Malberg JE, Potestio L, Ping J, Boikess S, Luo B, Schechter LE, Rizzo S, Rahman Z, Rosenzweig-Lipson S (2006) Anxiolytic-like activity of oxytocin in male mice: behavioral and autonomic evidence, therapeutic implications. Psychopharmacology (Berl) 185:218–225
Malberg JE, Platt B, Rizzo SJ, Ring RH, Lucki I, Schechter LE, Rosenzweig-Lipson S (2007) Increasing the levels of insulin-like growth factor-I by an IGF binding protein inhibitor produces anxiolytic and antidepressant-like effects. Neuropsychopharmacology 32:2360–2368
Hughes ZA, Liu F, Platt BJ, Dwyer JM, Pulicicchio CM, Zhang G, Schechter LE, Rosenzweig-Lipson S, Day M (2008) WAY-200070, a selective agonist of estrogen receptor beta as a potential novel anxiolytic/antidepressant agent. Neuropharmacology 54:1136–1142
Foreman MM, Hanania T, Eller M (2009) Anxiolytic effects of lamotrigine and JZP-4 in the elevated plus maze and in the four plate conflict test. Eur J Pharmacol 14:602:316–320
Stemmelin J, Cohen C, Terranova JP, Lopez-Grancha M, Pichat P, Bergis O, Decobert M, Santucci V, Françon D, Alonso R, Stahl SM, Keane P, Avenet P, Scatton B, le Fur G, Griebel G (2008) Stimulation of the beta3-Adrenoceptor as a novel treatment strategy for anxiety and depressive disorders. Neuropsychopharmacology 33:574–587
Wesołowska A, Nikiforuk A, Stachowicz K, Tatarczyńska E (2006) Effect of the selective 5-HT7 receptor antagonist SB 269970 in animal models of anxiety and depression. Neuropharmacology 51:578–586
Wesołowska A, Nikiforuk A (2007) Effects of the brain-penetrant and selective 5-HT6 receptor antagonist SB-399885 in animal models of anxiety and depression. Neuropharmacology 52:1274–1283
Grisel JE, Fleshner M, Watkins LR, Maier SF (1993) Opioid and nonopioid interactions in two forms of stress-induced analgesia. Pharmacol Biochem Behav 45:161–172
Fardin V, Oliveras JL, Besson JM (1984) A reinvestigation of the analgesic effects induced by stimulation of the periaqueductal gray matter in the rat: IR The production of behavioral side effects together with analgesia. Brain Res 306:105–123
Jacob JJ, Tremblay EC, Colombel MC (1994) Enhancement of nociceptive reactions by naloxone in mice and rats. Psychopharmacologia 37:217–223
Espejo EF, Mir D (1993) Structure of the rat’s behaviour in the hot plate test. Behav Brain Res 56:171–176
Espejo EF, Stinus L, Cador M, Mir D (1994) Effects of morphine and naloxone on behaviour in the hot plate test: an ethopharmacological study in the rat. Psychopharmacology 113:500–510
Ripoll N, Hascoët M, Bourin M (2006) The four-plates test: anxiolytic or analgesic paradigm? Prog Neuropsychopharmacol Biol Psychiatry 30:873–880
Drugan RC, Ryan SM, Minor TR, Maier SF (1984) Librium prevents the analgesia and shuttlebox escape deficit typically observed following inescapable shock. Pharmacol Biochem Behav 21:749–754
Gatch MB (1999) Effects of benzodiazepines on acute and chronic ethanol-induced nociception in rats. Alcohol Clin Exp Res 23:1736–1743
Nadeson R, Guo Z, Porter V, Gent JP, Goodchild CS (1996) Gamma-aminobutyric acidA receptors and spinally mediated antinociception in rats. J Pharmacol Exp Ther 278:620–626
Pakulska W, Czarnecka E (2001) Effect of diazepam and midazolam on the antinociceptive effect of morphine, metamizol and indomethacin in mice. Pharmazie 56:89–91
Rosland JH, Hole K (1990) Benzodiazepine-induced antagonism of opioid antinociception may be abolished by spinalization or blockade of the benzodiazepine receptor. Pharmacol Biochem Behav 37:505–509
Borges PC, Coimbra NC, Brandao ML (1988) Independence of aversive and pain mechanisms in the dorsal periaqueductal gray matter of the rat. Braz J Med Biol Res 21:1027–1031
Fasmer OB, Hunskaar S, Hole K (1989) Antinociceptive effects of serotonergic reuptake inhibitors in mice. Neuropharmacology 28:1363–1366
Otsuka N, Kiuchi Y, Yokogawa F, Masuda Y, Oguchi K, Hosoyamada A (2001) Antinociceptive efficacy of antidepressants: assessment of five antidepressants and four monoamine receptors in rats. J Anesth 15:154–158
Yokogawa F, Kiuchi Y, Ishikawa Y, Otsuka N, Masuda Y, Oguchi K, et al.(2002) An investigation of monoamine receptors involved in antinociceptive effects of antidepressants. Anesth Analg 95:163–168
Okuda K, Takanishi T, Yoshimoto K, Ueda S (2003) Trazodone hydrochloride attenuates thermal hyperalgesia in a chronic constriction injury rat model. Eur J Anaesthesiol 20:409–415
Schreiber S, Backer MM, Herman I, Shamir D, Boniel T, Pick CG (2000) The antinociceptive effect of trazodone in mice is mediated through both mu-opioid and serotonergic mechanisms. Behav Brain Res 114:51–56
Bourin M, Masse F, Dailly E, Hascoët M (2005) Anxiolytic-like effect of milnacipran in the four-plate test in mice: mechanism of action. Pharmacol Biochem Behav 81:645–656
David DJ, Renard CE, Jolliet P, Hascoet M, Bourin M (2003) Antidepressant-like effects in various mice strains in the forced swimming test. Psychopharmacology 166:373–382
Prado WA, Roberts MH (1985) An assessment of the antinociceptive and aversive effects of stimulating identified sites in the rat brain. Brain Res 340:219–228
Beyer CE, Dwyer JM, Platt BJ, Neal S, Luo B, Ling HP, Lin Q, Mark RJ, Rosenzweig-Lipson S, Schechter LE (2010) Angiotensin IV elevates oxytocin levels in the rat amygdala and produces anxiolytic-like activity through subsequent oxytocin receptor activation. Psychopharmacology (Berl) 209:303–311
Czopek A, Byrtus H, Kołaczkowski M, Pawłowski M, Dybała M, Nowak G, Tatarczyńska E, Wesołowska A, Chojnacka-Wójcik E (2010) Synthesis and pharmacological evaluation of new 5-(cyclo)alkyl-5-phenyl- and 5-spiroimidazolidine-2,4-dione derivatives. Novel 5-HT1A receptor agonist with potential antidepressant and anxiolytic activity. Eur J Med Chem 45:1295–1303
Massé F, Hascoët M, Bourin M (2005) alpha2-Adrenergic agonists antagonise the anxiolytic-like effect of antidepressants in the four-plate test in mice. Behav Brain Res 164:17–28
Massé F, Hascoët M, Dailly E, Bourin M (2006) Effect of noradrenergic system on the anxiolytic-like effect of DOI (5-HT2A/2 C agonists) in the four-plate test. Psychopharmacology (Berl) 83:471–481
Nic Dhonnchadha BA, Ripoll N, Clenet F, Hascoët M, Bourin M (2005) Implication of 5-HT2 receptor subtypes in the mechanism of action of antidepressants in the four plates test. Psychopharmacology (Berl) 179:418–429
Ripoll N, Hascoët M, Bourin M (2006) Implication of 5-HT(2A) subtype receptors in DOI activity in the four-plates test-retest paradigm in mice. Behav Brain Res 166:131–139
Massé F, Petit-Démoulière B, Dubois I, Hascoët M, Bourin M (2008) Anxiolytic-like effect of DOI microinjections into the hippocampus (but not the amygdala nor the PAG) in the mice test. Behav. Brain Res 188: 291–297
Petit-Demoulière B, Massé F, Cogrel N, Hascoët M, Bourin M (2009) Brain structures implicated in the four-plate test in naïve and experienced Swiss mice using injection of diazepam and the 5-HT2A agonist DOI. Behav Brain Res 204:200–205
Ripoll N, Nic Dhonnchadha BA, Sébille V, Bourin M, Hascoët M (2005) The four-plates test-retest paradigm to discriminate anxiolytic effects. Psychopharmacology (Berl) 180:73–83
File SE (1990) “One-trial tolerance to the anxiolytic effects of chlordiazepoxide in the plus-maze.” Psychopharmacology (Berl) 100:281–282
Petit-Demoulière B, Hascoët M, Bourin M (2008) Factors triggering abolishment of benzodiazepines effects in the Four-Plate Test–retest in mice. Eur Neuropsychopharmacol 18:41–47
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Hascoët, M., Bourin, M. (2011). The Four-Plate Test in Mice. In: Gould, T. (eds) Mood and Anxiety Related Phenotypes in Mice. Neuromethods, vol 63. Humana Press. https://doi.org/10.1007/978-1-61779-313-4_8
Download citation
DOI: https://doi.org/10.1007/978-1-61779-313-4_8
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-61779-312-7
Online ISBN: 978-1-61779-313-4
eBook Packages: Springer Protocols